HC Wainwright Reaffirms Buy Rating for Evaxion Biotech A/S (NASDAQ:EVAX)

Evaxion Biotech A/S (NASDAQ:EVAX)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $14.00 target price on the stock.

Separately, Lake Street Capital reduced their price objective on shares of Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, February 4th.

Evaxion Biotech A/S Trading Down 10.3 %

NASDAQ EVAX opened at $1.66 on Wednesday. The company has a current ratio of 1.00, a quick ratio of 2.80 and a debt-to-equity ratio of 7.99. Evaxion Biotech A/S has a 1-year low of $1.64 and a 1-year high of $22.05. The firm’s fifty day simple moving average is $2.44 and its 200-day simple moving average is $6.98. The company has a market capitalization of $1.95 million, a PE ratio of -1.14 and a beta of -0.25.

Evaxion Biotech A/S (NASDAQ:EVAX) last issued its earnings results on Tuesday, April 1st. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.19. The firm had revenue of $0.12 million during the quarter, compared to analysts’ expectations of $1.66 million. As a group, sell-side analysts anticipate that Evaxion Biotech A/S will post -0.15 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. Catalina Capital Group LLC bought a new stake in shares of Evaxion Biotech A/S (NASDAQ:EVAX) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned 2.98% of Evaxion Biotech A/S as of its most recent SEC filing. 11.04% of the stock is owned by hedge funds and other institutional investors.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.